These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal. Khedri M; Abnous K; Rafatpanah H; Ramezani M J Recept Signal Transduct Res; 2018 Feb; 38(1):31-36. PubMed ID: 29252078 [TBL] [Abstract][Full Text] [Related]
5. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma. Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363 [TBL] [Abstract][Full Text] [Related]
7. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma. Shu C; Li Q Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903 [TBL] [Abstract][Full Text] [Related]
8. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma. Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157 [TBL] [Abstract][Full Text] [Related]
9. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553 [TBL] [Abstract][Full Text] [Related]
10. Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC. Li X; Lian Z; Wang S; Xing L; Yu J Cancer Lett; 2018 Apr; 418():1-9. PubMed ID: 29309815 [TBL] [Abstract][Full Text] [Related]
11. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. Wang Y; Wu L; Tian C; Zhang Y Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997 [TBL] [Abstract][Full Text] [Related]
12. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity. Zhu H; You Y; Shen Z; Shi L Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402 [TBL] [Abstract][Full Text] [Related]
13. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389 [TBL] [Abstract][Full Text] [Related]
14. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254 [TBL] [Abstract][Full Text] [Related]
15. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036 [TBL] [Abstract][Full Text] [Related]
16. Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors. Shida Y; Nakazawa T; Matsuda R; Morimoto T; Nishimura F; Nakamura M; Maeoka R; Yamada S; Nakagawa I; Park YS; Yasukawa M; Tojo T; Tsujimura T; Nakase H Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576141 [TBL] [Abstract][Full Text] [Related]
17. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY Front Immunol; 2018; 9():727. PubMed ID: 29910795 [TBL] [Abstract][Full Text] [Related]
18. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196 [TBL] [Abstract][Full Text] [Related]
19. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938 [TBL] [Abstract][Full Text] [Related]